Handelsbanken Fonder AB Has $2.23 Million Position in Prothena Co. plc (NASDAQ:PRTA)

Handelsbanken Fonder AB increased its position in Prothena Co. plc (NASDAQ:PRTA) by 4.2% in the 4th quarter, according to its most recent disclosure with the Securities and Exchange Commission (SEC). The firm owned 61,400 shares of the biotechnology company’s stock after buying an additional 2,500 shares during the quarter. Handelsbanken Fonder AB’s holdings in Prothena were worth $2,231,000 as of its most recent filing with the Securities and Exchange Commission (SEC).

Other institutional investors and hedge funds also recently made changes to their positions in the company. China Universal Asset Management Co. Ltd. increased its stake in shares of Prothena by 99.0% in the third quarter. China Universal Asset Management Co. Ltd. now owns 1,375 shares of the biotechnology company’s stock valued at $66,000 after buying an additional 684 shares during the period. Headlands Technologies LLC bought a new stake in Prothena in the third quarter valued at approximately $74,000. Allspring Global Investments Holdings LLC boosted its holdings in Prothena by 58.3% in the third quarter. Allspring Global Investments Holdings LLC now owns 3,096 shares of the biotechnology company’s stock valued at $149,000 after acquiring an additional 1,140 shares during the last quarter. Zurcher Kantonalbank Zurich Cantonalbank boosted its holdings in Prothena by 12.0% in the third quarter. Zurcher Kantonalbank Zurich Cantonalbank now owns 7,464 shares of the biotechnology company’s stock valued at $360,000 after acquiring an additional 797 shares during the last quarter. Finally, Oppenheimer & Co. Inc. boosted its holdings in Prothena by 3.9% in the third quarter. Oppenheimer & Co. Inc. now owns 7,908 shares of the biotechnology company’s stock valued at $382,000 after acquiring an additional 295 shares during the last quarter. Institutional investors and hedge funds own 97.08% of the company’s stock.

Prothena Stock Performance

Prothena stock opened at $20.87 on Friday. Prothena Co. plc has a 52-week low of $19.65 and a 52-week high of $79.65. The stock’s 50 day moving average price is $25.37 and its two-hundred day moving average price is $32.14.

Prothena (NASDAQ:PRTA) last issued its earnings results on Thursday, February 15th. The biotechnology company reported ($1.26) earnings per share (EPS) for the quarter, missing analysts’ consensus estimates of ($1.23) by ($0.03). Prothena had a negative return on equity of 24.84% and a negative net margin of 160.91%. The firm had revenue of $0.32 million during the quarter, compared to the consensus estimate of $2.15 million. During the same quarter in the prior year, the business earned $0.12 earnings per share. Prothena’s revenue for the quarter was down 99.4% on a year-over-year basis. Analysts anticipate that Prothena Co. plc will post -4.88 earnings per share for the current fiscal year.

Wall Street Analyst Weigh In

PRTA has been the topic of several analyst reports. Cantor Fitzgerald reiterated an “overweight” rating on shares of Prothena in a report on Wednesday, April 10th. StockNews.com cut Prothena from a “hold” rating to a “sell” rating in a report on Monday, February 19th. Royal Bank of Canada reduced their target price on Prothena from $36.00 to $35.00 and set a “sector perform” rating on the stock in a report on Friday, February 16th. JMP Securities increased their price target on Prothena from $81.00 to $85.00 and gave the stock a “market outperform” rating in a report on Friday, February 16th. Finally, Bank of America restated a “neutral” rating and set a $38.00 price target (down from $68.00) on shares of Prothena in a report on Tuesday, January 30th. One equities research analyst has rated the stock with a sell rating, two have assigned a hold rating and five have given a buy rating to the company’s stock. According to MarketBeat.com, the stock has an average rating of “Moderate Buy” and an average target price of $68.14.

Prothena Profile

Prothena Corporation plc, a late-stage clinical biotechnology company, focuses on discovery and development of novel therapies to treat diseases caused by protein dysregulation in the United States. The company is involved in developing birtamimab, an investigational humanized antibody that is in Phase III clinical trial for the treatment of AL amyloidosis; Prasinezumab, a humanized monoclonal antibody, for the treatment of Parkinson's disease and other related synucleinopathies which is in Phase IIb clinical trial; NNC6019 that is in Phase lI clinical trial for the treatment of ATTR amyloidosis; and BMS-986446 and PRX012, which is in Phase I clinical trial for the treatment of Alzheimer's disease.